News & Events

Designing conditionally activated immune stimulators that attack cancer cells

As seen in Nature Biopharma Dealmakers

Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered and activated selectively in the tumor microenvironment to recruit a powerful antitumor immune response.

Read more